Adage Capital Partners
ANTX icon

Adage Capital Partners’s AN2 Therapeutics ANTX Stock Holding History

Adage Capital Partners’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.42M Buy
+1,000,000
New +$2.06M 0.01% 802
2025
Q2 		– Sell
-1,000,000
Closed -$1.36M – 851
2025
Q1 		$1.36M Buy
1,000,000
+687,385
+220% +$865K ﹤0.01% 780
2024
Q4 		$431K Hold
312,615
– – ﹤0.01% 841
2024
Q3 		$334K Hold
312,615
– – ﹤0.01% 822
2024
Q2 		$672K Hold
312,615
– – ﹤0.01% 811
2024
Q1 		$1.02M Sell
312,615
-588,057
-65% -$6.4M ﹤0.01% 792
2023
Q4 		$18.5M Sell
900,672
-4,884
-0.5% -$81.7K 0.04% 444
2023
Q3 		$14.6M Buy
+905,556
New +$10.3M 0.03% 479

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Adage Capital Partners's ANTX Position: Q1 2026 in Review

Adage Capital Partners opened a new position in AN2 Therapeutics (ANTX) in Q1 2026: 1,000,000 shares worth $3.42M. The stake represents 0.01% of the portfolio and ranks #802 among its holdings. This is a return to the name: Adage Capital Partners previously reported a position in ANTX as recently as Q1 2025.

Adage Capital Partners first reported a position in ANTX in Q3 2023 and has held it in 8 quarters since. The position peaked at $18.5M in Q4 2023. 52 funds tracked by Wall St. Rank hold ANTX as of Q1 2026.

  • Adage Capital Partners held 1,000,000 shares of AN2 Therapeutics worth $3.42M as of Q1 2026.
  • AN2 Therapeutics was a new Adage Capital Partners position in Q1 2026.
  • AN2 Therapeutics made up 0.01% of Adage Capital Partners's portfolio in Q1 2026, its #802 holding.
  • Adage Capital Partners first reported a position in AN2 Therapeutics in Q3 2023 and has held it in 8 quarters since.
  • Adage Capital Partners's AN2 Therapeutics position peaked at $18.5M in Q4 2023.
  • 52 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.